Mn Services Vermogensbeheer B.V. Reduces Position in Pfizer Inc. (NYSE:PFE)

Mn Services Vermogensbeheer B.V. reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 2,184,100 shares of the biopharmaceutical company’s stock after selling 47,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Pfizer were worth $63,208,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Olistico Wealth LLC bought a new position in Pfizer in the second quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer in the 2nd quarter worth approximately $29,000. Quarry LP acquired a new stake in shares of Pfizer in the second quarter worth $31,000. Financial Connections Group Inc. purchased a new stake in shares of Pfizer in the second quarter worth about $34,000. Finally, ESL Trust Services LLC acquired a new stake in shares of Pfizer during the 1st quarter worth approximately $37,000. 68.36% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Scott Gottlieb bought 1,000 shares of the company’s stock in a transaction dated Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the acquisition, the director now owns 10,000 shares of the company’s stock, valued at $282,400. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.

Pfizer Stock Performance

Pfizer stock traded down $0.11 on Monday, hitting $27.98. The company’s stock had a trading volume of 9,780,469 shares, compared to its average volume of 37,131,203. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm has a market cap of $158.55 billion, a P/E ratio of 37.96, a price-to-earnings-growth ratio of 0.90 and a beta of 0.67. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The company has a fifty day moving average price of $29.03 and a 200-day moving average price of $28.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The business had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.40%. Pfizer’s revenue was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 6.00%. Pfizer’s dividend payout ratio is currently 227.03%.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on PFE. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays increased their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group increased their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $28.00 to $34.00 in a research note on Wednesday, August 7th. Finally, Citigroup started coverage on shares of Pfizer in a research note on Friday, October 25th. They issued a “neutral” rating and a $30.00 price target for the company. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.